ReShape Lifesciences Inc (RSLS)

NASDAQ
2.870
-0.040(-1.37%)
After Hours
2.910
+0.040(+1.394%)
- Real-time Data
  • Volume:
    475,966
  • Bid/Ask:
    2.880/2.950
  • Day's Range:
    2.860 - 2.959

RSLS Overview

Prev. Close
2.91
Day's Range
2.86-2.959
Revenue
6.85M
Open
2.86
52 wk Range
2.16-32.31
EPS
-2.19
Volume
475,966
Market Cap
19.57M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,967,024
P/E Ratio
-
Beta
-1.25
1-Year Change
15.26%
Shares Outstanding
6,817,393
Next Earnings Date
Nov 05, 2021
What is your sentiment on ReShape Lifesciences Inc?
or
Market is currently closed. Voting is open during market hours.

ReShape Lifesciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

ReShape Lifesciences Inc Company Profile

ReShape Lifesciences Inc Company Profile

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Read More
  • Wow! Best earning ever! Go up!
    0
    • Best robot trader of the century 😂😂😂
      0
      • I’m in 🚀
        0
        • 12:52 PM EDT, 06/17/2021 $ RSLS is a total buy with PT of $18.5 12:52 PM EDT, 06/17/2021 --Alliance Global Partners Adjusts ReShape Lifesciences PT to $18.50 From $12, Maintains Buy Rating
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.